SAMHD1 is a barrier to antimetabolite-based cancer therapies.
Sean G RuddTorsten SchallerNikolas HeroldPublished in: Molecular & cellular oncology (2017)
The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytarabine-induced toxicity. Therefore, we propose targeting SAMHD1 as a strategy to potentiate cytarabine and possibly other antimetabolite-based therapies.
Keyphrases
- acute myeloid leukemia
- papillary thyroid
- high dose
- allogeneic hematopoietic stem cell transplantation
- squamous cell
- drug induced
- oxidative stress
- liver failure
- diabetic rats
- squamous cell carcinoma
- intensive care unit
- lymph node metastasis
- childhood cancer
- respiratory failure
- extracorporeal membrane oxygenation
- mesenchymal stem cells
- young adults
- acute respiratory distress syndrome